Organon shareholders approve merger with Sun Pharma
Rhea-AI Filing Summary
Organon & Co. held a special stockholder meeting on July 23, 2026 to vote on its pending merger with Sun Pharmaceutical Holdings USA, Inc. Stockholders owning 195,675,859 shares, representing 74.51% of the 262,609,433 shares outstanding as of June 15, 2026, were present, constituting a quorum.
Stockholders approved the Agreement and Plan of Merger, under which a Sun Pharma subsidiary will merge with and into Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. The merger agreement received 192,776,552 votes for, 2,573,118 against and 326,189 abstentions, with no broker non-votes. In a separate non-binding advisory vote, stockholders also approved merger-related compensation for named executive officers, with 185,141,986 votes for, 9,553,830 against and 980,043 abstentions.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding on record date: 262,609,433 shares
Shares represented at special meeting: 195,675,859 shares
Quorum percentage: 74.51%
+4 more
7 metrics
Shares outstanding on record date
262,609,433 shares
Common Stock outstanding and entitled to vote as of June 15, 2026 record date
Shares represented at special meeting
195,675,859 shares
Shares represented virtually or by proxy at the July 23, 2026 special meeting
Quorum percentage
74.51%
Percentage of total voting power represented at the special meeting
Votes for Merger Agreement
192,776,552 votes
Votes in favor of Proposal No. 1 to adopt the Merger Agreement
Votes against Merger Agreement
2,573,118 votes
Votes against Proposal No. 1 to adopt the Merger Agreement
Votes for advisory compensation proposal
185,141,986 votes
Votes in favor of Proposal No. 2 on merger-related executive compensation
Votes against advisory compensation proposal
9,553,830 votes
Votes against Proposal No. 2 on merger-related executive compensation
Key Terms
Agreement and Plan of Merger, record date, broker non-votes, non-binding, advisory basis
4 terms
Agreement and Plan of Merger regulatory
"relating to the merger transaction contemplated by the Agreement and Plan of Merger"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
record date regulatory
"As of the close of business on June 15, 2026, the record date for the Special Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
broker non-votes regulatory
"The proposal was approved by the votes indicated below, including Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory basis regulatory
"To approve, on a non-binding, advisory basis, the compensation that may be paid"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Organon (OGN) stockholders approve at the July 23, 2026 special meeting?
Stockholders approved the Agreement and Plan of Merger between Organon & Co. and Sun Pharmaceutical Holdings USA, Inc. Under this agreement, a Sun Pharma subsidiary will merge with Organon, and Organon will continue as a wholly owned subsidiary of Sun Pharma USA.
What was the quorum and voting power for Organon (OGN) at the special meeting?
A quorum was achieved with 195,675,859 shares of Common Stock represented virtually or by proxy, equal to 74.51% of the total voting power. As of the June 15, 2026 record date, 262,609,433 shares were outstanding and entitled to vote.
What will Organon’s (OGN) corporate structure be after the Sun Pharma transaction?
Under the approved Merger Agreement, Sun Pharma America, Inc. will merge with and into Organon, and Organon will survive the merger as a wholly owned subsidiary of Sun Pharma USA. Organon’s Common Stock currently trades on the NYSE under the symbol OGN.
AI-generated analysis. How Rhea-AI works. Not financial advice.
